Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Skye Bioscience, Inc.NMUS · Entity 8098 | 10% owner | March 13, 2017 | March 28, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Skye Bioscience, Inc.
Report date March 13, 2017 · Filed March 28, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,787,500 |
Reported balance
After 2017-03-13 transaction · row 1
1 source rowRow 1 · 2017-03-13 · Other · Disposed 119,700 · Balance 3,787,500 F1: The shares of common stock were transferred to a creditor as repayment of outstanding principal and accrued interest of certain promissory note upon maturity pursuant to the terms of such note. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock were transferred to a creditor as repayment of outstanding principal and accrued interest of certain promissory note upon maturity pursuant to the terms of such note.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2017 Filed Mar 28, 2017 14:52 UTC | Skye Bioscience, Inc. NMUS · Entity 8098 | OtherCommon Stock | 119,700 | $1.00 | $119,700.00 |
DisclosureSEC source: 0001140361-17-013540 · doc1.xml · nonDerivative · entry 1 Lapham Reg Alexander · CIK 0001624201 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,787,500 F1 · shares: The shares of common stock were transferred to a creditor as repayment of outstanding principal and accrued interest of certain promissory note upon maturity pursuant to the terms of such note. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.